Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F12%3A10132671" target="_blank" >RIV/00179906:_____/12:10132671 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11150/12:10132671 RIV/61989592:15110/12:33140642

Result on the web

<a href="http://dx.doi.org/10.1007/s12032-012-0195-y" target="_blank" >http://dx.doi.org/10.1007/s12032-012-0195-y</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s12032-012-0195-y" target="_blank" >10.1007/s12032-012-0195-y</a>

Result language

angličtina

Original language name

Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis

Original language description

Neoadjuvant chemotherapy is being increasingly used in the treatment of breast carcinoma. We performed a single-center retrospective analysis of the results of neoadjuvant therapy in 376 breast carcinoma patients treated with three different regimens combining doxorubicin and paclitaxel (AT), dose-dense doxorubicin and cyclophosphamide with sequential weekly paclitaxel (DD AC-P), or the combination of trastuzumab with chemotherapy (DD AC-PT). The expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor (HER)-2 was determined immunohistochemically. Pathological response was determined in 318 patients. Pathological complete response (pCR) was observed in 18% of patients. The pCR rate was significantlyhigher in patients treated with DD regimen (22 vs. 13%) and younger than 55 years (23 vs. 13%). The pCR rate was higher in patients with triple negative (TN) tumors (43%) and tumors over-expressing HER-2 (HER-2+; 28%) compared to patients

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FP - Other medical fields

OECD FORD branch

—

Project

<a href="/en/project/NS10286" target="_blank" >NS10286: Molecular cytogenetic predictors of adjuvant therapy in patients with triple negative breast carcinoma</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Medical Oncology

ISSN

1357-0560

e-ISSN

—

Volume of the periodical

29

Issue of the periodical within the volume

4

Country of publishing house

US - UNITED STATES

Number of pages

9

Pages from-to

2577-2585

UT code for WoS article

000309711600041

EID of the result in the Scopus database

—